Ozmosi | Dipotassium clorazepate Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Dipotassium clorazepate

Alternative Names: dipotassium clorazepate, clorazepate, clorazepate dipotassium, clorazepato, tranxene, gen-xene, tranxene sd, tranxene t-tab
Clinical Status: Inactive
Latest Update: 2025-09-08
Latest Update Note: Clinical Trial Update

Product Description

Clorazepate is used to relieve symptoms of anxiety and alcohol withdrawal. It is also used with other medicines to treat partial seizures. Clorazepate is a benzodiazepine. Benzodiazepines belong to the group of medicines called central nervous system (CNS) depressants, which are medicines that slow down the  (Sourced from: https://www.mayoclinic.org/drugs-supplements/clorazepate-oral-route/side-effects/drg-20072306?p=1)

Mechanisms of Action: GABA Modulator, GABA Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous, Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Belgium | Bulgaria | Canada | Chile | Colombia | Dominican Republic | France | Greece | Ireland | Israel | Italy | Lithuania | Luxembourg | Morocco | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Slovenia | Spain | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Kingdom | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: MIKEL URRETAVIZCAYARACHAGA
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Breastfeeding|Headache

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2018-000503-16

CLORMIG

P3

Active, not recruiting

Breastfeeding|Headache

2024-02-12

2022-03-13

Treatments